Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Ana Alfonso-Pierola, Marina Diaz Beya, Teresa Bernal, David Valcarcel, Montserrat Arnan, María Luz Amigo, Joaquin Sanchez-Garcia, Raúl Azibeiro Melchor, Blanca Xicoy, Fernando Ramos, Mar Tormo, Joan Bargay, Maria Teresa Cedena Romero, Leonor Arenillas, Jose Francisco Falantes, Ariane Unamunzaga, Lourdes Hermosin Ramos, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 3868.

https://doi.org/10.1182/blood-2025-3868

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Bone marrow immune and stromal niche remodeling in myelodysplastic neoplasm patients under erythropoietic therapies by 29-color full-spectrum flow cytometry

Claudia Pellin Jou, Iñaki Salvador Corres, Pamela Acha, Alba Puyuelo, Sara Garrido Paniagua, Pilar Velarde, Maria Landwehr, Ana Perez Gonzalez, Laura Gallur, Sílvia Saumell Tutusaus, Julia Montoro, Andres Jerez, Laura Palomo, David Valcarcel

Blood (2025) 146 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2025-3183

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Intermediate and high-risk clonal hematopoiesis in germline predisposition families

Sandra Novoa Jáuregui, Sara Torres-Esquius, Maria Gabarrós Subirà, Pamela Acha, Francisco Beas, Ana Maria Garrido, Marc Bosch-Schips, Claudia Pellin Jou, Adriana Oños, Sílvia Saumell Tutusaus, Ana Perez Gonzalez, Adoracion Blanco, David Valcarcel, Francesc Bosch Albareda, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2025-2058

Published: 2025

Journal Articles

Single-cell transcriptomics reveal long non-coding RNA dysregulation in PPP1R15B-EIF2A axis impairing erythroid maturation in myelodysplastic syndromes

Francisco Beas, Enrique Goñi, Aintzane Diaz-Mazkiaran, Teresa Ezponda, Ana Alfonso-Pierola, Andres Jerez, Felipe Prosper, David Valcarcel, Mikel Hernáez Arrazola

Blood (2025) 146 (Supplement 1): 2056.

https://doi.org/10.1182/blood-2025-2056

Published: 2025

Journal Articles

Clinical characteristics, treatment strategies, and response patterns in evans syndrome: Initial analysis from the spanish resti cohort

Maria Eva Mingot, Elena Sebastián Pérez, Javier Bañon Soria, Daniel Martinez Carballeira, Isabel González-gascón-y-Marín, Reyes Jimenez Barcenas, Gonzalo Caballero Navarro, David Valcarcel, Maria Cristina Pascual Izquierdo

Blood (2025) 146 (Supplement 1): 1263.

https://doi.org/10.1182/blood-2025-1263

Published: 2025

Journal Articles

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Valeria Santini, Matteo Della Porta, Rami Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcarcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer Zeidan

Blood (2025) 146 (Supplement 1): 792.

https://doi.org/10.1182/blood-2025-792

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Sara Torres-Esquius, Maria Gabarros-Subira, Maria Eugenia Rivero, Guillermo Ramil López, Lucia García Mañó, Felix Lopez, Concepción Fernandez, Francesca Guijarro, Marina Díaz-Beyá, Marta Pratcorona Canela, Pamela Acha, Sandra Novoa Jáuregui, Esperanza Tuset, Laura Palomo, David Valcarcel, Francesc Bosch Albareda, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 4998.

https://doi.org/10.1182/blood-2025-4998

Published: 2025

Journal Articles

Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Sara Torres-Esquius, Maria Gabarros-Subira, Carmelo Gurnari, Carlos Bravo-Perez, Guillermo Ramil López, Raquel De Paz Arias, Alejandro Sanz, Maria Muñoz Martinez, Francisco Beas, Sandra Novoa Jáuregui, Marta Pratcorona Canela, Silvia Saumell, Maria Teresa Voso, Jaroslaw Maciejewski, Pamela Acha, David Valcarcel, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 4997.

https://doi.org/10.1182/blood-2025-4997

Published: 2025

Journal Articles

Implementation of 2020 international guidelines in acquired hemophilia: Insights from a decade of national registry data in Spain

Blood (2025) 146 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2025-3077

Published: 2025

Journal Articles

Proliferation of mature plasmacytoid dendritic cells in RUNX1-mutated Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 7004.

https://doi.org/10.1182/blood-2025-7004

Published: 2025

Journal Articles

A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study

Blood (2025) 146 (Supplement 1): 733.

https://doi.org/10.1182/blood-2025-733

Published: 2025

Journal Articles

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Blood (2025) 146 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2025-2074

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Beyond TP53: Molecular IPSS-genes multihit status revisited

Blood (2025) 146 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2025-2090

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Bone marrow immune and stromal niche remodeling in myelodysplastic neoplasm patients under erythropoietic therapies by 29-color full-spectrum flow cytometry

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Intermediate and high-risk clonal hematopoiesis in germline predisposition families

Single-cell transcriptomics reveal long non-coding RNA dysregulation in PPP1R15B-EIF2A axis impairing erythroid maturation in myelodysplastic syndromes

Clinical characteristics, treatment strategies, and response patterns in evans syndrome: Initial analysis from the spanish resti cohort

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Implementation of 2020 international guidelines in acquired hemophilia: Insights from a decade of national registry data in Spain

Proliferation of mature plasmacytoid dendritic cells in RUNX1-mutated Acute Myeloid Leukemia

A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Beyond TP53: Molecular IPSS-genes multihit status revisited

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only